21-34880632-T-C
Variant summary
Our verdict is Uncertain significance. Variant got 5 ACMG points: 5P and 0B. PP3PS3_ModeratePM2_SupportingPM1_Supporting
This summary comes from the ClinGen Evidence Repository: NM_001754.5(RUNX1):c.433A>G (p.Arg145Gly) is a missense variant which has a REVEL score ≥ 0.88 (0.925) (PP3). Data from two or more secondary assays (FRET assay and SEUSS) demonstrate altered function, including decreased phosphorylation of RUNX1 and decreased gene expression (PS3_moderate; PMID:33692461, 32943879). This variant is located within the Runt Homology Domain (RHD; AA 89-204) but does not occur in an established hotspot residue (PM1_supporting). It is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2_supporting). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PS3_moderate, PP3, PM1_supporting, and PM2_supporting. LINK:https://erepo.genome.network/evrepo/ui/classification/CA16616277/MONDO:0011071/008
Frequency
Consequence
NM_001754.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 5 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hereditary thrombocytopenia and hematologic cancer predisposition syndrome Uncertain:1
NM_001754.5(RUNX1):c.433A>G (p.Arg145Gly) is a missense variant which has a REVEL score ≥ 0.88 (0.925) (PP3). Data from two or more secondary assays (FRET assay and SEUSS) demonstrate altered function, including decreased phosphorylation of RUNX1 and decreased gene expression (PS3_moderate; PMID: 33692461, 32943879). This variant is located within the Runt Homology Domain (RHD; AA 89-204) but does not occur in an established hotspot residue (PM1_supporting). It is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2_supporting). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PS3_moderate, PP3, PM1_supporting, and PM2_supporting. -
Hereditary thrombocytopenia and hematological cancer predisposition syndrome associated with RUNX1 Uncertain:1
In summary, this variant is a novel missense change with uncertain impact on protein function. It has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This variant is not present in population databases (ExAC no frequency) and has not been reported in the literature in individuals with a RUNX1-related disease. This sequence change replaces arginine with glycine at codon 145 of the RUNX1 protein (p.Arg145Gly). The arginine residue is moderately conserved and there is a moderate physicochemical difference between arginine and glycine. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at